Literature DB >> 35655443

Prevalence of antinuclear antibodies and rheumatoid factor titers in dogs with arthritis secondary to leishmaniosis (Leishmania infantum).

Theodora K Tsouloufi1, Konstantina Theodorou2, Michael J Day3, Ioannis L Oikonomidis1, Dimitrios Kasabalis4, Mathios E Mylonakis2, Manolis N Saridomichelakis4, Maria Kritsepi-Konstantinou1, Nectarios Soubasis2.   

Abstract

Dogs with infectious arthritis may occasionally exhibit positive serum antinuclear antibody (ANA) and rheumatoid factor (RF) titers; however, relevant data are sparse for arthritis secondary to canine leishmaniosis (CanL) caused by Leishmania infantum. We determined the prevalence of positive serum ANA and RF titers in dogs with arthritis secondary to CanL. Blood samples from adult, client-owned dogs with purulent arthritis secondary to CanL, without any comorbidities, were collected for diagnostic purposes. Serum ANA titers were measured by immunoperoxidase test and RF titers by the Rose-Waaler latex test. Twelve of 23 dogs enrolled prospectively in our study had clinical arthritis, and 11 of 23 had subclinical arthritis. Based on LeishVet clinical staging, 7 dogs had clinical stage II disease, 11 had clinical stage III disease, and 5 had stage IV. None of the 23 dogs was seropositive for ANA; 3 of 23 were positive for RF. ANA and/or RF seropositivity, in dogs with CanL-associated arthritis, appears to be weak, if present at all. Based on our results, positive serum ANA and RF titers should not be expected in dogs with arthritis secondary to CanL.

Entities:  

Keywords:  Leishmania infantum; anti-nuclear antibody; arthritis; canine; rheumatoid factor

Mesh:

Substances:

Year:  2022        PMID: 35655443      PMCID: PMC9266495          DOI: 10.1177/10406387221099030

Source DB:  PubMed          Journal:  J Vet Diagn Invest        ISSN: 1040-6387            Impact factor:   1.569


  16 in total

1.  Comparison of immunofluorescence and immunoperoxidase for demonstration of antinuclear antibodies on HEp-2 substrate.

Authors:  P G Tipping; W J Dimech; G O Littlejohn; S R Holdsworth
Journal:  Br J Rheumatol       Date:  1987-06

2.  Inheritance of serum autoantibody, reduced serum IgA and autoimmune disease in a canine breeding colony.

Authors:  M J Day
Journal:  Vet Immunol Immunopathol       Date:  1996-10       Impact factor: 2.046

3.  IgG subclasses of canine anti-erythrocyte, antinuclear and anti-thyroglobulin autoantibodies.

Authors:  M J Day
Journal:  Res Vet Sci       Date:  1996-09       Impact factor: 2.534

4.  Antinuclear antibodies in dogs with leishmaniasis.

Authors:  R Lucena; P J Ginel; R Lopez; M Novales; E Martin; J M Molleda
Journal:  Zentralbl Veterinarmed A       Date:  1996-06

5.  A retrospective clinical study of canine leishmaniasis in 150 dogs naturally infected by Leishmania infantum.

Authors:  P Ciaramella; G Oliva; R D Luna; L Gradoni; R Ambrosio; L Cortese; A Scalone; A Persechino
Journal:  Vet Rec       Date:  1997-11-22       Impact factor: 2.695

6.  Clinical and radiographic study of bone and joint lesions in 26 dogs with leishmaniasis.

Authors:  A Agut; N Corzo; J Murciano; F G Laredo; M Soler
Journal:  Vet Rec       Date:  2003-11-22       Impact factor: 2.695

7.  The laboratory identification of serum rheumatoid factor in the dog.

Authors:  D Bennett; D Kirkham
Journal:  J Comp Pathol       Date:  1987-09       Impact factor: 1.311

Review 8.  Pathologic mechanisms underlying the clinical findings in canine leishmaniasis due to Leishmania infantum/chagasi.

Authors:  A F Koutinas; C K Koutinas
Journal:  Vet Pathol       Date:  2014-02-07       Impact factor: 2.221

9.  Retrospective study of 14 cases of canine arthritis secondary to Leishmania infection.

Authors:  S Sbrana; V Marchetti; F Mancianti; G Guidi; D Bennett
Journal:  J Small Anim Pract       Date:  2014-04-03       Impact factor: 1.522

10.  Immunoglobulin isotype distribution of antinuclear antibodies in dogs with leishmaniasis.

Authors:  R Lucena; P J Ginel
Journal:  Res Vet Sci       Date:  1998 Nov-Dec       Impact factor: 2.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.